Pipeline

We are currently advancing a pipeline of small molecule, oral antagonists of the chemokine receptor CXCR4. We believe that inhibition of the CXCR4 receptor creates the potential to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer.

We are evaluating the safety and efficacy of our lead candidate, mavorixafor, a first-in-class oral CXCR4 antagonist, in a number of clinical programs: a fully enrolled Phase 3 clinical trial for the treatment of patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease; a Phase 1b clinical trial in combination with standard of care, ibrutinib for the treatment of patients with a rare B-cell lymphoma called Waldenstrom macroglobulinemia; and as monotherapy in a Phase 1b clinical trial for the treatment of patients with Severe Congenital Neutropenia (SCN) and other chronic neutropenia disorders.

We are also advancing several small-molecule pre-clinical candidates with desirable characteristics of next-generation oral CXCR4 antagonists.